| A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment MO Ogese, A Lister, L Farrell, J Gardner, L Kafu, SE Ali, A Gibson, ... Toxicological sciences 197 (1), 38-52, 2024 | 1 | 2024 |
| A low‐cost, sensitive and specific PCR‐based tool for rapid clinical detection of HLA‐B*35 alleles associated with delayed drug hypersensitivity reactions Y Li, P Deshpande, A Chopra, L Choo, A Gibson, EJ Phillips Hla 100 (6), 610-616, 2022 | | 2022 |
| An updated review of the diagnostic methods in delayed drug hypersensitivity A Copaescu, A Gibson, Y Li, JA Trubiano, EJ Phillips Frontiers in pharmacology 11, 573573, 2021 | 52 | 2021 |
| Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? A Sullivan, A Gibson, BK Park, DJ Naisbitt Expert Opinion on Drug Metabolism & Toxicology 11 (3), 357-368, 2015 | 20 | 2015 |
| Blister fluid as a cellular input for ex vivo diagnostics in drug-induced severe cutaneous adverse reactions improves sensitivity and explores immunopathogenesis A Awad, E Mouhtouris, CV Nguyen-Robertson, N Holmes, KYL Chua, ... Journal of Allergy and Clinical Immunology: Global 1 (1), 16-21, 2022 | 6 | 2022 |
| Characterization of healthy donor-derived T-cell responses specific to telaprevir diastereomers KA Alhilali, Z Al-Attar, A Gibson, A Tailor, X Meng, M Monshouwer, ... Toxicological Sciences 168 (2), 597-609, 2019 | 8 | 2019 |
| Characterization of primary human T-cell responses to p-phenylenediamine and Bandrowski's base A Gibson, K Seung-Hyun, L Faulkner, BK Park, DJ Naisbitt Clinical and Translational Allergy 4, 1-1, 2014 | | 2014 |
| Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity S Hammond, A Olsson-Brown, S Grice, A Gibson, J Gardner, ... Toxicological Sciences 186 (1), 58-69, 2022 | 21 | 2022 |
| Considerations for cross-reactivity between vancomycin and other glycopeptides N Nakkam, J Trubiano, A Gibson, EJ Phillips The Journal of Allergy and Clinical Immunology: In Practice 9 (8), 3233, 2021 | 3 | 2021 |
| Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A* 32: 01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype N Nakkam, A Gibson, E Mouhtouris, K Konvinse, N Holmes, KY Chua, ... The Journal of allergy and clinical immunology 147 (1), 403, 2021 | 8 | 2021 |
| Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗ 32: 01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. N Nakkam, A Gibson, E Mouhtouris, KC Konvinse, NE Holmes, KY Chua, ... The Journal of allergy and clinical immunology 147 (1), 403-405, 2020 | 27 | 2020 |
| Dapsone‐and nitroso dapsone‐specific activation of T cells from hypersensitive patients expressing the risk allele HLA‐B* 13: 01 Q Zhao, K Alhilali, A Alzahrani, M Almutairi, J Amjad, H Liu, Y Sun, L Sun, ... Allergy 74 (8), 1533-1548, 2019 | 45 | 2019 |
| Detection of primary T cell responses to drugs and chemicals in HLA-typed volunteers: implications for the prediction of drug immunogenicity L Faulkner, A Gibson, A Sullivan, A Tailor, T Usui, A Alfirevic, ... Toxicological Sciences 154 (2), 416-429, 2016 | 54 | 2016 |
| Development of an improved T-cell assay to assess the intrinsic immunogenicity of haptenic compounds MO Ogese, J Watkinson, A Lister, L Faulkner, A Gibson, A Hillegas, ... Toxicological Sciences 175 (2), 266-278, 2020 | 18 | 2020 |
| Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis N Hama, R Abe, A Gibson, EJ Phillips The Journal of Allergy and Clinical Immunology: In Practice 10 (5), 1155 …, 2022 | 92 | 2022 |
| Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy BL Mangan, RK McAlister, JM Balko, DB Johnson, JJ Moslehi, A Gibson, ... British journal of clinical pharmacology 86 (9), 1778-1789, 2020 | 42 | 2020 |
| Genetic and nongenetic factors that may predispose individuals to allergic drug reactions A Gibson, M Ogese, M Pirmohamed Current Opinion in Allergy and Clinical Immunology 18 (4), 325-332, 2018 | 15 | 2018 |
| Genomic risk factors driving immune-mediated delayed drug hypersensitivity reactions Y Li, P Deshpande, RJ Hertzman, AM Palubinsky, A Gibson, EJ Phillips Frontiers in Genetics 12, 641905, 2021 | 23 | 2021 |
| Glycolysis: An early marker for vancomycin‐specific T‐cell activation J Gardner, S Hammond, R Jensen, A Gibson, MS Krantz, M Ardern‐Jones, ... Clinical & Experimental Allergy 54 (1), 21-33, 2024 | | 2024 |
| HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure JL Goldman, JO Miller, N Miller, R Eveleigh, A Gibson, EJ Phillips, ... The pharmacogenomics journal 22 (2), 124-129, 2022 | 8 | 2022 |
